RXO Analyst Ratings
Oppenheimer Reiterates Outperform on RXO, Maintains $31 Price Target
Oppenheimer Maintains RXO Inc(RXO.US) With Buy Rating, Maintains Target Price $31
Barclays Maintains RXO Inc(RXO.US) With Buy Rating, Maintains Target Price $32
Barclays Sticks to Its Buy Rating for RXO, Inc. (RXO)
Jefferies Maintains RXO Inc(RXO.US) With Buy Rating, Maintains Target Price $31
BofA Securities Maintains RXO Inc(RXO.US) With Hold Rating, Cuts Target Price to $30
SIG Maintains RXO Inc(RXO.US) With Sell Rating, Raises Target Price to $20
RXO Analyst Ratings
Susquehanna Maintains Negative on RXO, Raises Price Target to $20
Barclays Maintains RXO Inc(RXO.US) With Buy Rating, Maintains Target Price $32
A Quick Look at Today's Ratings for RXO Inc(RXO.US), With a Forecast Between $31 to $32
Jefferies Maintains Buy on RXO, Lowers Price Target to $31
Jefferies Maintains RXO Inc(RXO.US) With Buy Rating, Cuts Target Price to $31
Benchmark Co. Maintains RXO Inc(RXO.US) With Hold Rating
RXO Analyst Ratings
RXO, Inc. (RXO) Receives a Buy From Barclays
RXO Price Target Raised to $26.00/Share From $25.00 by JP Morgan
RXO Analyst Ratings
UBS Maintains Neutral on RXO, Raises Price Target to $31